Feature / NICE update

NICE UPDATE

NICE published the following guidance in May:

Technology appraisal guidance

• TA- 312 alemtuzumab for treating relapsing – remitting multiple sclerosis – Alemtuzumab is recommended as an option, within its marketing authorisation, for treating adults with active relapsing-remitting multiple sclerosis. For the prevalent population, the cost of people switching to alemtuzumab per 100,000 population is estimated to be £137,400 over five years. The annual cost impact associated with implementing the recommendations for people being newly prescribed alemtuzumab per 100,000 population is estimated to be £20,800 from year five onwards.
• TA313 ustekinumab for psoriatic arthritis (second line after DMARDs) – Ustekinumab is not recommended within its marketing authorisation for treating active psoriatic arthritis. This covers use alone or in combination with methotrexate in adults when the response to previous non-biological disease-modifying anti-rheumatic drug (DMARD) therapy has been inadequate. As a result, no significant costs are anticipated.

Public health guidance

• PH53 – overweight and obese adults: lifestyle weight management services – The annual resource impact of implementing the recommendation from year five onwards per 100,000 population is around £28,000. This assumes the proportion of people referred to lifestyle weight management programmes increases from around 0.3 to 1.3% of overweight or obese adults.